Plasma Lipoproteins, Lipolytic Enzymes, and Very Low Density Lipoprotein Triglyceride Turnover in Cushing’s Syndrome*

1983 ◽  
Vol 57 (3) ◽  
pp. 619-626 ◽  
Author(s):  
MARJA-RIITTA TASKINEN ◽  
ESKO A. NIKKILÄ ◽  
RISTO PELKONEN ◽  
TIMO SANE
Keyword(s):  
Cushing’S Syndrome ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cushing's Syndrome ◽  
Plasma Lipoproteins ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Lipolytic Enzymes

Studies on the Thromboplastic Effect of Human Plasma Lipoproteins

1976 ◽  
Vol 35 (01) ◽  
pp. 178-185 ◽  
Author(s):  
Helena Sandberg ◽  
Lars-Olov Andersson
Keyword(s):  
High Density Lipoprotein ◽  
Human Plasma ◽  
Platelet Rich Plasma ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Plasma Lipoproteins ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Free Plasma ◽  
Good Agreement

SummaryHuman plasma lipoprotein fractions were prepared by flotation in the ultracentrifuge. Addition of these fractions to platelet-rich, platelet-poor and platelet-free plasma affected the partial thromboplastin and Stypven clotting times to various degrees. Addition of high density lipoprotein (HDL) to platelet-poor and platelet-free plasma shortened both the partial thromboplastin and the Stypven time, whereas addition of low density lipoprotein and very low density lipoprotein (LDL + VLDL) fractions only shortened the Stypven time. The additions had little or no effect in platelet-rich plasma.Experiments involving the addition of anti-HDL antibodies to plasmas with different platelet contents and measuring of clotting times produced results that were in good agreement with those noted when lipoprotein was added. The relation between structure and the clot-promoting activity of various phospholipid components is discussed.

The Passage of Apoproteins from Plasma Lipoproteins into the Lipoproteins of Peripheral Lymph in Man

1977 ◽  
Vol 53 (3) ◽  
pp. 221-226
Author(s):  
D. Reichl ◽  
N. B. Myant ◽  
J. J. Pflug ◽  
D. N. Rudra
Keyword(s):  
Intravenous Injection ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Plasma Lipoproteins ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Intermediate Density Lipoprotein ◽  
Peripheral Lymph ◽  
Apoprotein B ◽  
Intermediate Density

1. The transport of apoprotein B from the lipoproteins of plasma into the lipoproteins of lymph draining the foot has been studied in four men with type III hyperlipoproteinaemia. 2. Three subjects were given autologous 125I-labelled very-low-density lipoprotein (VLDL) and 131I-labelled low-density lipoprotein (LDL) by intravenous injection; the fourth was given autologous 125I-labelled VLDL and 131I-labelled intermediate-density lipoprotein (IDL) plus LDL. 3. The 125I/131I ratios in serum and lymph apoprotein B, and the 125I and 131I specific radioactivities of apoprotein B in VLDL, IDL and LDL from serum and lymph, indicate that apoprotein B in the circulating VLDL can reach peripheral lymph without the intermediacy of circulating LDL.

scholarly journals A Global Review Article on Hyperlipidemia

2021 ◽  
Vol 68 (1) ◽  
Author(s):  
Mumthaj. P ◽  
Natarajan. P ◽  
Janani. A.M ◽  
Vijay. J ◽  
Gokul. V
Keyword(s):  
Plasma Lipids ◽  
Medical Condition ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Review Article ◽  
Plasma Lipoproteins ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Factors Associated

Hyperlipidemia is a medical condition characterized by an increase in one or more of the plasma lipids, including triglycerides, cholesterol, cholesterol esters, phospholipids and or plasma lipoproteins including very low-density lipoprotein and low-density lipoprotein along with reduced high-density lipoprotein levels. This elevation of plasma lipids is among the leading risk factors associated with cardiovascular diseases. Introduction, type of lipoprotein, classification of hyperlipidemia, Complications of hyperlipidaemia, causes; Symptoms of hypelipedemia, Pathogenesis of hyperlipidemia, Pathogenesis of hyperlipidemia, diagnosis, prevention, treatments.

Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism

2014 ◽  
Vol 111 (03) ◽  
pp. 518-530 ◽  
Author(s):  
Monireh Dashty ◽  
Mohammad Motazacker ◽  
Johannes Levels ◽  
Marcel de Vries ◽  
Morteza Mahmoudi ◽  
...  
Keyword(s):  
Human Plasma ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Protein S ◽  
The Body ◽  
Plasma Lipoproteins ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Coagulation Proteins ◽  
Associated Proteins

SummaryApart from transporting lipids through the body, the human plasma lipoproteins very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) are also thought to serve as a modality for intra-organismal protein transfer, shipping proteins with important roles in inflammation and thrombosis from the site of synthesis to effector locations. To better understand the role of VLDL and LDL in the transport of proteins, we applied a combination of LTQ ORBITRAP-XL (nLC-MS/MS) with both in-SDS-PAGE gel and in-solution tryptic digestion of pure and defined VLDL and LDL fractions. We identified the presence of 95 VLDL-and 51 LDL-associated proteins including all known apolipoproteins and lipid transport proteins, and intriguingly a set of coagulation proteins, complement system and anti-microbial proteins. Prothrombin, protein S, fibrinogen γ, PLTP, CETP, CD14 and LBP were present on VLDL but not on LDL. Prenylcysteine oxidase 1, dermcidin, cathelicidin antimicrobial peptide, TFPI-1 and fibrinogen α chain were associated with both VLDL and LDL. Apo A-V is only present on VLDL and not on LDL. Collectively, this study provides a wealth of knowledge on the protein constituents of the human plasma lipoprotein system and strongly supports the notion that protein shuttling through this system is involved in the regulation of biological processes. Human diseases related to proteins carried by VLDL and LDL can be divided in three major categories: 1 – dyslipidaemia, 2 – atherosclerosis and vascular disease, and 3 – coagulation disorders.

Effects of dietary protein on composition and turnover of apoproteins in plasma lipoproteins of rabbits

1981 ◽  
Vol 59 (8) ◽  
pp. 642-647 ◽  
Author(s):  
D. C. K. Roberts ◽  
M. E. Stalmach ◽  
M. W. Khalil ◽  
J. C. Hutchinson ◽  
K. K. Carroll
Keyword(s):  
Soy Protein ◽  
Plasma Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Plasma Lipoproteins ◽  
Dietary Proteins ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Isolated Soy Protein ◽  
Intermediate Density

The hypercholesterolemia and atherosclerosis produced in rabbits by feeding cholesterol-free, semipurified diets are due to the use of casein as the protein component of such diets and can be prevented by replacing the casein with isolated soy protein. To investigate the reasons for the differing effects of these dietary proteins on plasma cholesterol levels, plasma lipoproteins were isolated from rabbits fed semipurified diets containing either casein or isolated soy protein, labeled with 125I, and reinjected into rabbits fed one or other of these two diets. 125I-labeled apoproteins of intermediate density lipoprotein, isolated from rabbits on either diet, turned over more rapidly in rabbits fed soy protein compared with those fed casein. 125I-labeled apoproteins of very low density lipoprotein from rabbits fed soy protein were transferred to high density lipoprotein more rapidly than those from rabbits fed casein. In this case, the results were determined primarily by the diet fed to the donor rabbits, but the diet fed to the recipients also appeared to have some influence. The apoproteins of plasma lipoproteins from rabbits fed casein or soy protein were separated by isoelectric focussing and tentatively identified by comparison of their isoelectric points with those of apoproteins from human plasma lipoproteins. The concentration of apoprotein E was markedly increased in the very low density and intermediate density lipoproteins of casein-fed rabbits, and apoprotein C was also increased in the very low density lipoprotein of rabbits fed casein, compared with those fed soy protein. Effects of dietary proteins on plasma cholesterol may be secondary to their effects on the composition and metabolism of the protein components of plasma lipoproteins.

scholarly journals An Overview on Hyperlipidemia

2021 ◽  
pp. 543-555
Author(s):  
D. A. Helen Sheeba ◽  
R. Gandhimathi
Keyword(s):  
Plasma Lipids ◽  
Medical Condition ◽  
Plasma Cholesterol ◽  
Low Density Lipoprotein ◽  
Research Work ◽  
Density Lipoprotein ◽  
High Plasma ◽  
Plasma Lipoproteins ◽  
Very Low Density Lipoprotein ◽  
Low Density

Introduction: Hyperlipidemia is a medical condition indicated by an increase in one or more plasma lipids, such as triglycerides, cholesterol, cholesterol esters, phospholipids, and/or plasma lipoproteins, such as very low-density lipoprotein and low-density lipoprotein, as well as decreased levels of high-density lipoprotein. This increase in plasma lipids is one of the most important risk factors for cardiovascular disease. In the meanwhile, statins and fibrates remain the most common anti-hyperlipidemic drugs for treating high plasma cholesterol and triglycerides. Conclusion: Hence this review focused to study of hyperlipidemia. This review is useful to research work in hyperlididemia.

Sign in / Sign up

Export Citation Format

Share Document